Background: This American Thoracic Society, European Respiratory Society, Japanese
Respiratory Society, and Asociación Latinoamericana de Tórax guideline updates prior …

Background Interstitial lung disease (ILD) is a common manifestation of systemic sclerosis
and a leading cause of systemic sclerosis–related death. Nintedanib, a tyrosine kinase …

Acute exacerbation of idiopathic pulmonary fibrosis has been defined as an acute, clinically
significant, respiratory deterioration of unidentifiable cause. The objective of this …

Rationale: In interstitial lung disease complicating systemic sclerosis (SSc-ILD), the optimal
prognostic use of baseline pulmonary function tests (PFTs) and high-resolution computed …

We performed a genome-wide association study of non-Hispanic, white individuals with fibrotic
idiopathic interstitial pneumonias (IIPs; n = 1,616) and controls (n = 4,683), with follow-up …

As of May 6, 2020, nearly 3· 7 million people have been infected and around 260 000 people
have died from coronavirus disease 2019 (COVID-19) worldwide. 1 Almost all COVID-19-…

Background Idiopathic pulmonary fibrosis (IPF) is a progressive debilitating lung disease
with considerable morbidity. Heterogeneity in epidemiologic studies means the full impact of …

Background At present, no approved pharmacotherapies are available for unclassifiable
interstitial lung disease (ILD), which is characterised by progressive fibrosis of the lung. We …

Rationale: Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease of unknown
cause that leads to respiratory failure and death within 5 years of diagnosis. Overt respiratory …

Idiopathic pulmonary fibrosis (IPF) is a chronic progressive disease of unknown cause
characterized by relentless scarring of the lung parenchyma leading to reduced quality of life and …